



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 4 : C12Q 1/68, G01N 33/53 C12N 15/00	A1	(11) International Publication Number: WO 86/ 07387 (43) International Publication Date: 18 December 1986 (18.12.86)
(21) International Application Number: PCT/US86/01280 (22) International Filing Date: 13 June 1986 (13.06.86) (31) Priority Application Number: 744,800 (32) Priority Date: 13 June 1985 (13.06.85) (33) Priority Country: US (71) Applicants: AMGEN [US/US]; 1900 Oak Terrace Lane, Thousand Oaks, CA 91320 (US). ABBOTT LABORATORIES [US/US]; 14th Street & Sheridan Road, North Chicago, IL 60064 (US). (72) Inventors: SNITMAN, David, L. ; 1475 Ithaca Drive, Boulder, CO 80303 (US). STROUPE, Stephen, D. ; 606 Roosevelt Drive, Libertyville, IL 60048 (US).		(74) Agent: BORUN, Michael, F.; Marshall, O'Toole, Gers- tein, Murray & Bicknell, Two First National Plaza, Chicago, IL 60603 (US). (81) Designated States: AT (European patent), AU, BE (Eu- ropean patent), CH (European patent), DE (Euro- pean patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European pa- tent), NL (European patent), SE (European patent). Published <i>With international search report.</i>
(54) Title: METHOD AND KIT FOR PERFORMING NUCLEIC ACID HYBRIDIZATION ASSAYS (57) Abstract A method and a kit for the isolation and quantitative detection of a selected target nucleic acid sequence from solu- tion employing two probes. A first probe is complementary to one portion of the target and is covalently attached to a first complexing agent (e.g., either an antigen or an antibody). The second probe is complementary to a different portion of the target and is associated with a reporter group. Following hybridization of the target and two probes in solution, a solid support coated with a second complexing agent (i.e., a corresponding antibody or antigen) capable of binding to the first complexing agent on the first probe is employed to immobilize the target-probe hybrid complex. A plurality of types of first probes may be used. Each type is attached to the same sort of complexing agent but each includes a nucleic acid se- quence which is complementary to a different portion of the target.		

- 1 -

"METHOD AND KIT FOR PERFORMING
NUCLEIC ACID HYBRIDIZATION ASSAYS"

5

Background

The present invention relates in general to methods and kits for performing nucleic acid hybridization assays and in particular to methods and kits for immobilizing a target nucleic acid on a solid support by employing a labelled nucleotide probe, a nucleotide probe attached to a first complexing agent, and a second complexing agent attached to a support.

One characteristic property of nucleic acid, which forms the heritable material of all living organisms, is its ability to form sequence-specific hydrogen bonds with a nucleic acid having a complementary sequence of nucleotides. This ability of nucleic acids to form sequence-specific hydrogen bonds (i.e., to hybridize) with complementary strands of nucleic acid has been exploited in techniques generally called hybridization assays.

In a hybridization assay, a nucleic acid having a known sequence is used as a probe to search a sample for a "target" complementary sequence. Labelling of the hybrid formed by the probe and the target permits the detection and quantitation of complementary sequence in the sample.

Because all strains of a particular microorganism share a genetic component in the form of nucleic acids susceptible to diagnosis by means of a hybridization assay, such hybridization assays are valuable research and medical tools. Detection of specific target nucleic acids enables accurate diagnosis of bacterial, fungal and viral disease states in humans, animals and plants. Additionally, the ability to probe

- 2 -

for a specific nucleotide sequence is of potential use in the identification and diagnosis of human genetic disorders.

One approach to labelling the probe for
5 detecting a hybrid involves binding a radioisotope (e.g., ^{32}P or ^{125}I) to the probe.

Non-radioactive labelling systems are also available. A first type employs a label which may be directly and covalently attached to the probe, such as
10 fluorescent or chemiluminescent molecules (e.g., fluorescein or acridinium). A second type has a portion which is covalently attached to the DNA probe and non-covalently attached to labelled macromolecules.

An example of the second type of non-
15 radioactive labelling system involves a biotin molecule which is covalently attached to a DNA probe and which forms a complex with fluorescent- or chemiluminescent- "labelled" avidin (or avidin derivative such as streptavidin). Another example of the second type of
20 non-radioactive labelling system is an antigen- "labelled" DNA probe which forms a complex with a fluorescent- or chemiluminescent-labelled antibody.

In the second type of labelling system, a probe is "labelled" with a reporter group to enable
25 detection. A reporter is an agent which is used to associate a signal with a probe for indicating the presence or location of the probe. The signal itself, which is directly perceptible, may be generated by a separate or separable signal molecule. A label is
30 properly a type of reporter which incorporates a signal.

Signal amplification may be achieved for biotin- or antigen-labelled DNA probes via the respective formation of a complex with avidin or with antibodies which may in turn be either covalently or
35 non-covalently associated with an enzyme. [Leary, et al., Proc.Natl.Acad.Sci. (USA), 80: 4045-4049 (1983)].

- 3 -

This reporter group may then be incubated with the appropriate enzymatic substrate to generate a detectable signal which indicates the presence of target in the hybridization complex.

5 One approach to the attachment of labels to probes is described in Ward, European Patent Application No. 63,879. Ward discloses the preparation of probes having a biotin reporter molecule covalently attached to a purine or a pyrimidine ring. Selected biotinylated
10 purines and pyrimidines are then directly incorporated within the phosphodiester backbone of nucleic acids of the probe by enzymatic means. In order to demonstrate that biotin-labelled native (double-stranded) DNA may be recognized by avidin, streptavidin or biotin-specific
15 antibodies, Ward, et al. employ affinity chromatography. A complementary strand of DNA is synthesized on a single strand of DNA by a DNA polymerase from biotin- or iminobiotin-labelled purines or pyrimidines. The resulting, labelled, double-
20 stranded DNA is selectively retained on an avidin-or a streptavidin-sepharose affinity column, as compared to non-labelled DNA. Ward, supra, at pages 24-26.

A biotin-labelled nucleic acid is employed in one approach to in situ hybridization in which biotin-
25 labelled RNA is hybridized with denatured DNA in a chromosome squash. Polymethacrylate spheres are covalently attached to avidin which in turn binds to the biotin, thereby labelling portions of the DNA hybridized with the RNA. Manning, et al., Chromosoma (Berl.), 53:
30 107-117 (1975). In addition, avidin-coated, polymethacrylate spheres have been employed in affinity chromatography to isolate biotin-labelled strands of DNA carrying a particular gene. Manning, et al., Biochemistry, 16: 1364-1370 (1977).

35 In another approach to labelling for in situ hybridization, advantage is taken of the naturally-

- 4 -

occurring bond between ribosomal protein and a pseudoribosomal gene in Drosophila. Antibodies are raised against the ribosomal protein and attached to polymethacrylate spheres which serve as labels for electron microscopy. Chooi, et al., Mol.Gen.Genet., 182: 245-251 (1981).

The formation of a complex between an antigenic substance being assayed and one or more antibodies is also the basis for another type of biological detection technique called an immunoassay. Antibodies are white blood cell-produced proteins which are capable of combining with an antigen in a reaction which is specific for that antigen. Both antigens and antibodies may be referred to as immunological agents. An antibody only combines with certain portions (antigenic determinants) of the surface of the antigen, so that the antibody is specific to the degree that the determinant with which it combines is not also found on other antigens. At least one member of the antigen/antibody complex may be coupled to a signal molecule which permits detection, quantitative analysis on separation of the antigen/antibody complex from uncomplexed labelled antigen or antibody and other constituents of the sample. Antibodies of any type may be employed in immunoassays including polyclonal antibodies, a mixture of antibodies directed to different antigenic determinants, and monoclonal antibodies, antibodies directed to a single antigenic determinant.

Both immunoassays and hybridization techniques are employed in two-site or "sandwich" assays. In sandwich assays a target substance having the ability to form hybrid or immune complexes at two different places on the target at one time is detected.

Typically, a sandwich immunoassay involves coupling a monoclonal antibody directed to a first

- 5 -

antigenic determinant to a solid support and exposing the support-coupled antibody to a sample containing a substance bearing the first and a second antigenic determinant. This results in the removal of the antigenic substance from the sample by the formation of a primary antibody-antigen complex which is bound to the support. Subsequent exposure of this complex to a second, labelled monoclonal antibody directed toward a second antigenic determinant on the antigenic substance creates an antibody-antigen-antibody sandwich which may be separated from the sample solution and measured.

[See, e.g., David, et al., U.S. Patent No.4,376,110.]

Sandwich hybridization assays include a two-step assay and a one-step assay. A two-step sandwich hybridization procedure involves the use of an immobilized target nucleic acid which is exposed in a first step to a first nucleic acid probe having a first portion complementary to the target and having a second portion which is not complementary to the target. In a second step, a second, labelled nucleic acid probe which is complementary to the second portion of the first probe is allowed to hybridize to the first probe, forming a "sandwich" with the first probe between the target and the second probe. Dunn, et al., Cell, 12: 23-36 (1977). The sandwich hybridization procedure is relatively easy to perform and is not seriously affected by protein or other biological contaminants. Ranki, et al., Gene, 21: 77-85 (1983). However, a two-step sandwich hybridization assay involves considerable delay associated with immobilization of the sample on a filter.

A one-step sandwich assay involves the use of a first nucleic acid probe immobilized on a filter. This first nucleic acid probe is complementary to a first portion of a target nucleic acid. In one step, the filter-bound first probe is exposed to a sample to

- 6 -

be searched for the target nucleic acid sequence and to a second, labelled nucleic acid probe complementary to a second portion of the target nucleic acid, which portion is separate from (i.e., non-overlapping with) the portion of the target to which the first probe is complementary. Ranki, et al., U.S. Patent No. 4,486,539. This one-step technique eliminates the delay caused by immobilization of a sample on a filter; eliminates differences between the types of treatment required for binding ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) to certain types of support inasmuch as the first probe may be selected to suit the support; and is even less sensitive to contaminating materials in the sample, e.g., mucus, than is a direct hybridization assay where the target is bound to the support. Ranki, et al., Curr.Top. Microbiol. Immunol., 104: 307-318 (1983). Nevertheless, leakage of the first probe from the support during hybridization occurs frequently and drastically diminishes the sensitivity of the assay.

Although both immunoassays and hybridization diagnostics are more rapid than conventional tests which require viable organisms and two to three days' culture, the antigens produced in a particular disease may vary from patient to patient and from one strain of a bacterium to another or from one strain of a virus to another, so that immunological diagnosis may be difficult. On the other hand, all strains of a bacterium or of a virus share a genetic component in the form of nucleic acids susceptible to diagnosis through the use of a nucleic acid probe.

Nevertheless, it is neither easy nor convenient to attach a single-stranded nucleic acid probe directly to a solid support for use in a sandwich hybridization assay. For example, the attachment of a nucleic acid to a nitrocellulose sheet involves fixing

- 7 -

the nucleic acid by contact with the sheet for 12-15 hours and baking the nucleic acid onto the sheet for two hours. See, e.g., Thomas, Proc. Natl. Acad. Sci.(USA), 77: 5201 (1980). Such preparation of a DNA-coated
5 nitrocellulose sheet may easily consume as much as a full working day, a factor which limits the clinical usefulness of nucleic acid hybridization.

Furthermore, because the nucleic acid probe is sequence-specific for a particular target molecule, the
10 procedure for attaching the probe to the support must be performed for each target molecule to be detected. Thus, in order to detect a number of different DNA sequences, a diagnostic laboratory must prepare an equal number of types of supports.

15 In addition, it generally takes longer to hybridize complementary strands of nucleic acid than it does, for example, to form an immunological complex between an antigen and an antibody. Hybridization itself is much more quickly accomplished in solution
20 than it is where one of the complementary sequences is attached to a solid support.

Affinity chromatographic techniques may be employed to isolate and purify nucleic acids [see, e.g., Inouye, et al., J.Biol.Chem., 23: 8125-8129 (1973)] or
25 tRNA [Miller, et al., Biochim.Biophys.Acta, 366: 188-198 (1974)] or tRNA cistrons [Salomon, et al., Biochemistry, 14: 4046-4050 (1975)]. However, these techniques rely upon the difficult step of forming antibodies to specific bases in a nucleic acid (Inouye, et al., supra;
30 Salomon, et al., supra) or upon the use of a derivatized, naturally-occurring ribonucleic acid (tRNA) (Miller, et al., supra) and are thus not readily applied in general to hybridization assays.

Thus, there exists a continuing interest and
35 need in the art for easy, convenient and rapid nucleic acid hybridization "sandwich" assays capable of

- 8 -

accurately detecting target molecules in a sample.

Brief Summary

5 A method according to the present invention
for the isolation and quantitative detection of a
selected target nucleic acid sequence from solution
involves hybridizing the target nucleic acid sequence in
solution to a first single-stranded nucleic acid probe
10 which has a sequence complementary to a selected portion
of the target sequence and which is therefore capable of
hybridizing therewith. The first probe sequence is
covalently attached to a first complexing agent. A
second single-stranded nucleic acid probe, which has a
15 sequence complementary to a different selected portion
of the target sequence than that which is complementary
to the first probe, hybridizes to the target. A
detectable reporter group is attached to the second
probe sequence.

20 Following solution hybridization, the method
according to the present invention further involves
immobilizing the hybrid sequence by adding to the
hybridization solution a second complexing agent bound
to a solid support capable of binding to the first
25 complexing agent on the first probe. There is thus
obtained a sandwich comprising the second complexing
agent-support, complexed with the first complexing
agent-first probe hybridized to the target, in turn
hybridized to the second probe. An assay is then
30 performed to detect and quantitate the bound reporter.

 A kit according to the present invention is
used for performing a hybridization assay on a sample
containing a selected target nucleic acid sequence from
solution. In this kit a first probe has a nucleic acid
35 sequence complementary to a first portion of the target
nucleic acid sequence and is attached to a first

- 9 -

complexing agent. A second single-stranded nucleic acid probe associated with the first nucleic acid probe has a nucleic acid sequence complementary to a second portion of the target sequence and is associated with the first probe. A reporter group is attached to the second nucleic acid probe. A solid support, also associated with the first nucleic acid probe, is attached to a second complexing agent which has a first complexing agent-binding portion.

Another method according to the present invention increases the capture efficiency associated with immobilizing a target nucleic acid sequence on a solid support. This method involves exposing the target nucleic acid sequence to at least two first probes, each having a nucleic acid sequence complementary to a different portion of the target nucleic acid sequence and each having a support-binding portion. In solution, the target nucleic acid sequence is hybridized to at least one of the first probes. The support-binding portion of the at least one of the first probes attaches to a first probe-binding portion on a solid support.

Another kit according to the present invention is useful for performing a hybridization assay on a sample containing a target nucleic acid sequence. The kit includes at least two first probes, each of which has a nucleic acid sequence complementary to a different portion of the target nucleic acid sequence. A second probe is associated with the first probes. The second probe has a sequence which is complementary to a portion of the target nucleic acid sequence that is separate from any portion complementary to any first probe. The second probe is also attached to a reporter group. A solid support is also associated with the first probes and has a first probe-binding portion.

Other aspects and advantages of the present invention will become apparent to those skilled in the

- 10 -

art upon consideration of the following detailed description.

Detailed Description

5

In a preferred embodiment of the method according to the present invention, a target nucleic acid sequence in solution may be detected or quantified by measuring the amount of a signal associated with an immobilized "sandwich" hybrid by conventional methods. The method is also useful in separating a hybridized target sequence from a solution where detection is not required. The method according to the present invention may be employed where the target oligonucleotide sequence is a deoxyribonucleic or ribonucleic acid sequence. In either case, depending on preference for a DNA-DNA, RNA-RNA, or DNA-RNA hybridization between the first probe, labelled second probe, and target, the probe sequences may be deoxyribonucleic or ribonucleic acid sequences.

15
20

The method is desirably employed on a double-stranded target sequence when the double-stranded sequence is denatured prior to use in the hybridization and is also useful for detection of single-stranded target sequences. The target sequence employed in this method may be of any length but preferably greater than about 20 residues in length.

25

The first probe sequence itself may be any nucleic acid sequence capable of covalently binding to the selected first complexing agent and having at least a portion designed to complement and to stably hybridize with a portion of the target sequence. The first complexing agent, which is covalently attached to the first probe, may be an antigen, such as fluorescein or an antibody, such as anti-fluorescein; or may be biotin or avidin; or may be a lectin, such as concanavalin A or

30

35

- 11 -

a carbohydrate having, for example, α -glucosyl residues or α -mannosyl residues specific for concanavalin A.

A lectin is a protein which has combining groups that react with specific carbohydrate components of another molecule to form a complex in a fashion similar to the interaction of an antibody with an antigen. Biotin, a vitamin, is an imidazole derivative which combines with avidin, a protein found in eggwhite, to form a biotin-avidin complex. Thus antigens and the antibodies which bind to them, lectins and the carbohydrate components to which they bind, and biotin and avidin, all may be distinguished as complexing agents, forming non-covalent bonds, from nucleic acids which are sequence-specific hybridizing agents, forming hydrogen bonds.

Several techniques may be employed to generate single-stranded polynucleotide probes for use in hybridization. A probe sequence complementary to a desired "target" sequence may be obtained: as a messenger RNA sequence corresponding to a target sequence; or complementary DNA obtained from reverse transcription of messenger RNA by the enzyme reverse transcriptase; or as genomic DNA obtained from the target genome by endonuclease digestion.

A probe sequence may be "amplified" by insertion into a DNA plasmid, such as pBR322, which will replicate in a bacterial host cell. Plasmid DNA is double-stranded and may be labelled by well-known nick translation procedures.

Alternatively, a probe sequence may be amplified by inserting the desired sequence into a single-stranded virus, such as the bacteriophage M13. The virus containing the probe sequence thereafter infects the bacterial culture and multiplies, making billions of copies of the probe sequence attached to viral DNA. The viral clone DNA may be isolated as

- 12 -

either single-stranded or double-stranded DNA. Double-stranded viral DNA may be labelled by nick translation. Single-stranded viral DNA may be rendered detectable through use of primed synthesis of complementary strand DNA using labelled nucleotides according to the procedures of Hu, et al., Gene, 17: 271-277 (1982). See Ranki, et al., Gene, 21: 77-85 (1983), which relates to M13 and pBR322 amplification systems for generating single-stranded probes for use in sandwich hybridization assays.

Like the first probe, the second probe may have any nucleic acid sequence which is different than that of the first probe and which is designed to complement and hybridize with the target at a portion of the target separate from (i.e., not overlapping) the portion to which the first probe hybridizes.

A reporter group may be covalently attached to the second probe. The reporter group may be a radioisotopic label, such as ^{125}I , ^{32}P , or the like. Alternatively, chelating moieties, such as ethylene diamine tetraacetic acid (EDTA) or diethyltriamino pentacetic acid (DTPA), may be employed to attach heavy metal labels to the probe. Appropriate heavy metal labels include ^{57}Co , ^{63}Ni , ^{111}In , ^{99}Tc , ^{55}Fe , ^{51}Cr , and the like. Non-isotopic labels, e.g., fluorescent compounds and chemiluminescent compounds, may also be employed in the method according to the present invention. Non-radioactive reporter groups which may be attached to the second probe include the enzyme alkaline phosphatase linked, for example, by biotin or avidin, to the second probe. Incubation in a solution of a methylumbelliferone phosphate substrate results in fluorescence produced by the action of the enzyme on the substrate.

Any solid support to which a complexing agent may be bound is useful in this method, including both

- 13 -

porous and non-porous, polymeric and non-polymeric supports. Examples of a solid support suitable for use in the method include silicates in general and glass, silica gel, and controlled pore glass in particular; 5 cellulose and nitrocellulose paper; polystyrene; latex and rubbers; and fluorocarbon resins, such as Teflon® and the like.

The second complexing agent bound to the support may be any agent which forms a complex with the 10 first complexing agent on the first probe. For example, the second complexing agent may be an antibody (e.g., IgG, IgM, or IgA), including a monoclonal antibody such as anti-fluorescein antibody where the antigen on the first probe is fluorescein.

15 As is clear to one skilled in the art, the present invention provides several advantages over the conventional attachment of a first nucleic acid probe to a solid support. Because a single combination of first and second immunological agents may be used with a wide 20 variety of probe and target sequences, the present invention eliminates the need for a laboratory to prepare a support specific to each sequence to be detected. Furthermore, to the extent that hybridization according to the present invention occurs between 25 complementary strands in solution rather than between one in solution and another on a solid support, the hybridization procedure proceeds more quickly. Furthermore, complex formation is much more rapid than hybridization so that the use of complex formation 30 rather than hybridization to attach the target to a support reduces assay time even further. Also, attachment of antibodies, antigens, lectins, carbohydrates, biotin or avidin to a solid support does not require as many steps and is not as time-consuming 35 as is the attachment of a sequence of nucleic acid to a solid support. Cf., e.g., Thomas, Proc. Natl. Acad.

- 14 -

Sci. (USA), 77: 5201-5205 (1980).

Thus, the present invention provides the means for accomplishing hybridization diagnostic tests much more easily, rapidly, and conveniently.

5 The following examples illustrate the practice of the method of the present invention. Specifically demonstrated are hybridization assays employing the two-probe system to detect and quantitate the amount of desired target sequence in a solution.

10 For use in the solution hybridization procedures of the following examples, a single-stranded phage containing either the (+) plus (coding) strand or the (-) minus (anticoding) strand of the Herpes Simplex Virus Type I (HSV-I) glycoprotein D (gD) gene was
15 employed as the target sequence. A portion of the double-stranded gene sequence is set out in Table I below, the bottom strand being the anticoding strand. This sequence has been published in Watson, et al.,
20 Science, 218: 381-384 (1982). Portions of the plus and minus strands have been employed as probes according to the present invention. These single-stranded probe
25 sequences have been designated on Table I by a lettered line drawn above the coding strand of the gene, or by a lettered and numbered line drawn below the anticoding
30 strand of the gene.

35

- 15 -

TABLE I

10				20				30				40					
GTG	GCC	CCG	GCC	CCC	AAC	AAA	AAT	CAC	GGT	AGC	CCG	GCC	GTG				
TAC	CGG	GGC	CGG	GGG	TTG	TTT	TTA	GTG	CCA	TCG	GGC	CGG	CAC				
50				60				70				80					
TGA	CAC	TAT	CGT	CCA	TAC	CGA	CCA	CAC	CGA	CGA	ACC	CCT	AAG				
ACT	GTG	ATA	GCA	GGT	ATG	GCT	GGT	GTG	GCT	GCT	TGG	GGA	TTC				
90				100				110				120					
GGG	GAG	GGG	CCA	TTT	TAC	GAG	GAG	GAG	GGG	TAT	AAC	AAA	GTC				
CCC	CTC	CCC	GGT	AAA	ATG	CTC	CTC	CTC	CCC	ATA	TTG	TTT	CAG				
130				140				150				160					
TGT	CTT	TAA	AAA	GCA	GGG	GTT	AGG	GAG	TTG	TTC	GGT	CAT	AAG				
ACA	GAA	ATT	TTT	CGT	CCC	CAA	TCC	CTC	AAC	AAG	CCA	GTA	TTC				
170				180				190				200				210	
CTT	CAG	CGC	GAA	CGA	CCA	ACT	ACC	CCG	ATC	ATC	AGT	TAT	CCT				
GAA	GTC	GCG	CTT	GCT	GGT	TGA	TGG	GGC	TAG	TAG	TCA	ATA	GGA				
R-1																	
220				230				240				250					
TAA	GGT	CTC	TTT	TGT	GTG	GTG	CGT	TCC	GGT	ATG	GGG	GGG	ACT				
ATT	CCA	GAG	AAA	ACA	CAC	CAC	GCA	AGG	CCA	TAC	CCC	CCC	TGA				
260				270				280				290					
GCC	GCC	AGG	TTG	GGG	GCC	GTG	ATT	TTG	TTT	GTC	GTC	ATA	GTG				
CGG	CGG	TCC	AAC	CCC	CGG	CAC	TAA	AAC	AAA	CAG	CAG	TAT	CAC				
300				310				320				330					
GGC	CTC	CAT	GGG	GTC	CGC	GGC	AAA	TAT	GCC	TTG	GCG	GAT	GCC				
CCG	GAG	GTA	CCC	CAG	GCG	CCG	TTT	ATA	CGG	AAC	CGC	CTA	CGG				

- 16 -

340 350 360 370 B

TCT CTC AAG ATG GCC GAC CCC AAT CGC TTT CGC GGC AAA GAC
AGA GAG TTC TAC CGG CTG GGG TTA GCG AAA GCG CCG TTT CTG

380 390 400 410 420

CTT CCG GTC CTG GAC CAG CTG ACC GAC CCT CCG GGG GTC CGG
GAA GGC CAG GAC CTG GTC GAC TGG CTG GGA GGC CCC CAG GCC

A-1

430 440 450 460

C

CGC GTG TAC CAC ATC CAG GCG GGC CTA CCG GAC CCG TTC CAG
GCG CAC ATG GTG TAG GTC CGC CCG GAT GGC CTG GGC AAG GTC

470 480 490 500

D

CCC CCC AGC CTC CCG ATC ACG GTT TAC TAC GCC GTG TTG GAG
GGG GGG TCG GAG GGC TAG TGC CAA ATG ATG CCG CAC AAC CTC

B-1

510 520 530 540

CGC GCC TGC CGC AGC GTG CTC CTA AAC GCA CCG TCG GAG GCC
GCG CGG ACG GCG TCG CAC GAG GAT TTG CGT GGC AGC CTC CGG

C-1

550 560 570 580

E

CCC CAG ATT GTC CGC GGG GCC TCC GAA GAC GTC CGG AAA CAA
GGG GTC TAA CAG GCG CCC CGG AGG CTT CTG CAG GCC TTT GTT

D-1

590 600 610 620 630

CCC TAC AAC CTG ACC ATC GCT TGG TTT CGG ATG GGA GGC AAC
GGG ATG TTG GAC TGG TAG CGA ACC AAA GCC TAC CCT CCG TTG

640 650 660 670

TGT GCT ATC CCC ATC ACG GTC ATG GAG TAC ACC GAA TGC TCC
ACA CGA TAG GGG TAG TGC CAG TAC CTC ATG TGG CTT ACG AGG

E-1

- 17 -

680 690 700 710
 G
 TAC AAC AAG TCT CTG GGG GCC TGT CCC ATC CGA ACG CAG CCC
 ATG TTG TTC AGA GAC CCC CGG ACA GGG TAG GCT TGC GTC GGG
 F-1

720 730 740 750
 CGC TGG AAC TAC TAT GAC AGC TTC AGC GCC GTC AGC GAG GAT
 GCG ACC TTG ATG ATA CTG TCG AAG TCG CGG CAG TCG CTC CTA
 G-3

760 770 780 790 I
 AAC CTG GGG TTC CTG ATG CAC GCC CCC GCG TTT GAG ACC GCC
 TTG GAC CCC AAG GAC TAC GTG CGG GGG CGC AAA CTC TGG CGG
 G-1

800 810 820 830 840
 GGC ACG TAC CTG CGG CTC GTG AAG ATA AAC GAC TGG ACG GAG
 CCG TGC ATG GAC GCC GAG CAC TTC TAT TTG CTG ACC TGC CTC
 H-1

850 860 870 880
 J
 ATT ACA CAG TTT ATC CTG GAG CAC CGA GCC AAG GGC TCC TGT
 TAA TGT GTC AAA TAG GAC CTC GTG GCT CGG TTC CCG AGG ACA

890 900 910 920
 AAG TAC GCC CTC CCG CTG CGC ATC CCC CCG TCA GCC TGC CTC
 TTC ATG CGG GAG GGC GAC GCG TAG GGG GGC AGT CCG ACG GAG
 I-1

930 940 950 960
 TCC CCC CAG GCC TAC CAG CAG GGG GTG ACG GTG GAC AGC ATC
 AGG GGG GTC CGG ATG GTC GTC CCC CAC TGC CAC CTG TCG TAG
 J-3 J-1

970 980 990 1000
 GGG ATG CTG CCC CGC TTC ATC CCC GAG AAC CAG CGC ACC GTC
 CCC TAC GAC GGG GCG AAG TAG GGG CTC TTG GTC GCG TGG CAG
 K-1

1010				1020				1030				1040				1050			
$\dot{\text{G}}$ CC	GTA	TAC	$\dot{\text{A}}$ GC	TTG	AAG	ATC	$\dot{\text{G}}$ CC	GGG	TGG	$\dot{\text{C}}$ AC	GGG	CCC	$\dot{\text{A}}$ AG						
CGG	CAT	ATG	TCG	AAC	TTC	TAG	CGG	CCC	ACC	GTG	CCC	GGG	TTC						

1060 1070 1080 1090

GCC CCA TAC [•]ACG AGC ACC CTG [•]CTG CCC CCG [•]GAG CTG TCC [•]GAG
CGG GGT ATG TGC TCG TGG GAC GAC GGG GGC CTC GAC AGG CTC

L-1

1100				1110				1120			1130		
ACC	CCC	AAC	GCC	ACG	CAG	CCA	GAA	CTC	GCC	CCG	GAA	GAC	CCC
TGG	GGG	TTG	CGG	TGC	GTC	GGT	CTT	GAG	CGG	GGC	CTT	CTG	GGG
M-1													

1140				1150		1160				1170			
GAG	GAT	TCG	GCC	CTC	TTG	GAG	GAC	CCC	GTG	GGG	ACG	GTG	GCG
CTC	CTA	AGC	CGG	GAG	AAC	CTC	CTG	GGG	CAC	CCC	TGC	CAC	CGC

1180			1190			1200			1210				
CCG	CAA	ATC	CCA	CCA	AAC	TGG	CAC	ATC	CCG	TCG	ATC	CAG	GAC
GGC	GTT	TAG	GGT	GGT	TTG	ACC	GTG	TAG	GGC	AGC	TAG	GTC	CTG
N-1							O-1						

1220		1230				1240		1250		1260			
G [•] CC	GCG	ACG	CCT [•]	TAC	CAT	CCC	CCG [•]	GCC	ACC	CCG [•]	AAC	AAC	ATG [•]
<u>CGG</u>	<u>CGC</u>	TGC	GGA	ATG	GTA	<u>GGG</u>	<u>GGC</u>	<u>CGG</u>	TGG	<u>GGC</u>	TTG	TTG	TAC
P-1													

			1270				1280				1290				1300
GGC	CTG	ATC	GCC	GGC	GCG	GTG	GGC	GGC	AGT	CTC	CTG	GCA	GCC		
CCG	GAC	TAG	CGG	CCG	CGC	CAC	CCG	CCG	TCA	GAG	GAC	CGT	CGG		

1310				1320				1330				1340			
CTG	GTC	ATT	TGC	GGA	ATT	GTG	TAC	TGG	ATG	CAC	CGC	CGC	ACT		
GAC	CAG	TAA	ACG	CCT	TAA	CAC	ATG	ACC	TAC	GTG	GCG	GCG	TGA		

- 19 -

1350	1360	1370	1380
CGG AAA GCC CCA AAG CGC ATA CGC CTC CCC CAC ATC CGG GAA			
GCC TTT CGG GGT TTC GCG TAT GCG GAG GGG GTG TAG GCC CTT			
		Q-1	

1390	1400	1410	1420
GAC GAC CAG CCG TCC TCG CAC CAG CCC TTG TTT TAC TAG ATA			
CTG CTG GTC GGC AGG AGC GTG GTC GGG AAC AAA ATG ATC TAT			
		S-1	

1430	1440	1450	1460	1470
CCC CCC CTT AAT GGG TGC GGG GGG GTC AGG TCT GCG GGG TTG				
GGG GGG GAA TTA CCC ACG CCC CCC CAG TCC AGA CGC CCC AAC				

1480	1490	1500	1510
GGA TGG GAC CTT AAC TCC ATA TAA AGC GAG TCT GGA AGG GGG			
CCT ACC CTG GAA TTG AGG TAT ATT TCG CTC AGA CCT TCC CCC			

1520	1530	1540	1550
GAA AGG CGG ACA GTC GAT AAG TCG GTA GCG GGG GAC GCG CAC			
CTT TCC GCC TGT CAG CTA TTC AGC CAT CGC CCC CTG CGC GTG			
	T-1		

1560	1570	1580	1590
CTG TTC CGC CTG TCG CAC CCA CAG CTT TTT CGC GAA CCG TCC			
GAC AAG GCG GAC AGC GTG GGT GTC GAA AAA GCG CTT GGC AGG			

1600
CGT TTT CGG GAT
GCA AAA GCC CTA

- 20 -

Three different targets are used in the examples. A first single-stranded phage target, phage 2 (φ2), contains 1,360 bases of the HSV-I D (gD) gene (i.e., bases 167 through 1,526, initiation codon nucleotide number 241 cloned into a plasmid, M13mpl8. The minus strand sequence of gD in φ2 is employed as a target complementary to the (+) plus strand probes identified above. A second single-stranded phage target, NPE #1, contains the entire 2.9 kilobases of the HSV-I gD sequence and is cloned into M13mpl8. The (+) plus strand sequence of gD in NPE #1 is cloned to provide a target complementary to the (-) minus probes identified above. Lastly, a double-stranded plasmid target, BamHI-J, is a BamHI restriction fragment of HSV-I which contains the entire 2.9 kilobases of the HSV-IgD sequence, along with 3.3 kilobases of surrounding HSV-I sequences. BamHI-J was cloned into the plasmid pBR322 and this plasmid was used as a double-stranded target for mimicking hybridization to HSV-I virus. See Roizman, et al., Curr. Top. Microbiol. Immunol., 104: 273 (1983).

The following examples describe a series of experiments demonstrating various aspects of the present invention.

Example 1 shows the ability of an antibody-coated support to capture a hybridization sandwich comprising two probes bound to a target. Example 2 illustrates the increase in capture efficiency obtained through the use of multiple antigen labelled probes. Example 3 demonstrates the effects of target concentration on the efficiency and sensitivity of the hybridization assay according to the present invention. Example 4 illustrates the utility of the present invention in detecting a radioactively-labelled hybridization sandwich. Example 5 shows the effectiveness of the present invention for detecting a

- 21 -

non-radioactively-labelled hybridization sandwich.
Example 6 illustrates the usefulness of the method according to the present invention in detecting the presence of a double-stranded DNA target.

5

Example 1

The ability of an antibody-coated solid support to capture a hybridization sandwich formed by two probes and a target was tested. An oligonucleotide first probe was labelled with an antigen at its 5' end. A second probe was an oligonucleotide carrying a reporter group. A portion of the target was complementary to each probe.

Specifically, the first probe was oligonucleotide G as described above. Such 5' labelling of oligonucleotide G may be accomplished with fluorescein.

Oligonucleotide G was 5' fluorescein labelled by reacting a 5' amine functionalized oligonucleotide G with fluorescein isothiocyanate. The 5' amine functionalized oligonucleotide G was formed by reacting oligonucleotide G bound by its 3' end to a solid support with a phosphoramidite having the general formula $[(CH_3)_2CH]_2NP(OCH_3)O(CH_2)_8NH(DMT)$ wherein DMT is a dimethoxytrityl group.

In the synthesis of this phosphoramidite, about 8ml of diazomethane-ether solution were added to 159.2 mg (1 mmole) of ω -aminocaprylic acid (available from Aldrich Chemical, Milwaukee, Wisconsin) in 10 ml of methanol. The methanol was evaporated to yield 174.9mg of ω -aminocaprylic acid methyl ester. Next, 173mg (1 mmole) of the ω -aminocaprylic acid methyl ester, 1 mmole of dimethoxytrityl chloride, and 1 mmole of diisopropylethyl amine were added to 5 ml of anhydrous tetrahydrofuran under an argon atmosphere at 0°C. This

- 22 -

mixture was warmed to 25°C and stirred for 1 hour. The solvent was evaporated and the crude product was diluted with 50 ml of ethyl acetate and washed successively with two portions of water, saturated bicarbonate, and brine.

- 5 The product was dried over anhydrous magnesium sulfate and evaporated to yield 460 mg of a dimethoxytrityl derivative of the ω -aminocaprylic acid methyl ester (ACAM-DMT).

- 10 To 0.17mmoles of ACAM-DMT in 1ml of anhydrous tetrahydrofuran under an argon atmosphere at -78°C was added 1.24 ml of 1 molar lithium aluminum hydride in tetrahydrofuran. This reaction mixture was stirred for 5 minutes at -78°C and was then stirred for 30 minutes at 25°C before being diluted with 10 ml of 5% H₂O in
15 tetrahydrofuran, 200 ml of ether, 3 g of cellite, and 0.5 g of anhydrous magnesium sulfate. The resulting mixture was stirred for 30 minutes and filtered to yield an alcohol having the general formula HO(CH₂)₈NH-DMT.

- 20 To 0.72 mmoles of HO(CH₂)₈NH-DMT in 10ml of anhydrous dichloromethane was added 0.76 mmoles of diisopropyl ethyl amine and 0.76 mmoles of chloro-N,N'-diisopropylaminomethoxy phosphene (as available from American Bionuclear, Emeryville, California). This mixture was stirred for 40 minutes at 25°C, and then
25 diluted with 50 ml of ethyl acetate and washed with four portions of brine. The product of this reaction was the phosphoramidite used for labelling oligonucleotide G above.

- 30 The second probe was oligonucleotide A, which had been labelled with ³²P according to the procedure of Maniatis, et al., Cell, 15: 687 (1978). The specific activity of the probe on the date of use was 3.2x10⁶ cpm/pmole.

- 35 Oligonucleotide G without a 5' fluorescein label was used as a first probe control. A second control probe, having the sequence

- 23 -

5'CATGATCTTGC GGTCGGATTCTTC3', which does not complement any of the target sequence, was also ^{32}P -labelled and had a specific activity on the date of use of 3.2×10^6 cpm/picomole.

5 The target used was single-stranded $\phi 2$.
Single-stranded $\phi 2$ is complementary to the first and second probes and to the first probe control, but not to the second control probe.

 As a support, one-quarter-inch polystyrene
10 beads of the sort available from Pierce Chemical, Rockland, Illinois, were coated with fluorescein antibody (anti-fluorescein). Anti-fluorescein production was induced in rabbits. The anti-fluorescein was purified by ammonium sulfate precipitation, followed by
15 DEAE cellulose chromatography. In solution, the anti-fluorescein had an affinity of approximately 10^{12} and quenched the fluorescence of fluorescein by about 99%.

 To prepare an anti-fluorescein-coated bead, the bead is cleaned by ultrasonication for 15 seconds in
20 10mM NaHCO_3 buffer at pH 8. After ultrasonication, the beads are washed in deionized water until all fines are removed. Approximately 200 beads are covered by 40 ml of 10 mM NaHCO_3 . Next, 7 ml of purified anti-fluorescein at a concentration of 0.57 mg/ml is added. The beads
25 are incubated for approximately 65 hours at room temperature. After incubation, the beads are washed with deionized water and air-dried on a suction filter.

 Each of the anti-fluorescein-coated beads is capable of binding approximately 1 pmole of fluorescein,
30 as demonstrated by incubation of single beads with 1.5ml of 1 nM fluorescein in TDX buffer (0.1 M NaPO_4 , pH 7.5; 0.1% NaN_3 ; 0.1% bovine gammaglobulin). During 20 hours of incubation at 25°C , 97% of the fluorescence was removed from solution. After washing the beads three
35 times in 5ml of deionized water and blotting the beads dry after each wash, the beads were incubated in 0.1 M

- 24 -

NaOH for 10 minutes, in which 60% of the originally applied amount of fluorescein was released into solution. Thus, each bead has approximately 0.9 pmole of fluorescein binding capacity.

5 (1) A series of capture experiments employing 5'-fluorescein-labelled oligonucleotides, 5'-biotin-labelled oligonucleotides (both 3'-³²P end-labelled), and kinased ³²P-labelled oligonucleotides and polystyrene beads coated with anti-fluorescein were run
10 under the following conditions.

With 200 µg/ml denatured sheared salmon sperm DNA (Sigma Chemical Company, St. Louis, Missouri) containing 1 picomole of one of the ³²P-labelled oligonucleotides, 100 µl of TDX buffer (0.1M sodium
15 phosphate, pH 7.5; 0.1% NaN₃; and 0.01% bovine gamma globulin, Sigma Chemical Company, St. Louis, Missouri) was mixed. An anti-fluorescein-coated polystyrene bead was added to this solution. After incubating this system for 18 hours at 25°C, the bead was removed and
20 washed for 5 minutes in 1 ml of TDX buffer at 25°C. The bead was then counted in a scintillation counter.

The stability of the antibody complex on the bead was tested by washing the bead for 5 minutes at increasing temperatures. The capture efficiency and
25 stability of a series of such beads is shown in Table II.

30

35

- 25 -

TABLE II
Percent cpm Capture

5	Temper- <u>ature</u>	<u>Complexes</u>	
		<u>5' fluorescein- labelled complex</u>	<u>5' biotin- labelled complex</u> <u>5' ³²P- labelled complex</u>
10	25	63	4 3
	35	61	1 0
	45	56	0 0
	55	51	0 0
	65	42	0 0
15	75	35	0 0
	85	20	0 0
	95	0	0 0

As illustrated by Table II, these beads have a high capture efficiency and stability of the sort which is useful in a hybridization capture system. Because little or no biotin or ³²P-labelled oligonucleotide binds to these beads, indicating little non-specific binding to the beads, the background in such a system is very low.

(2) In order to more precisely determine the rate of capture of a fluorescein-labelled oligonucleotide by a fluorescein antibody-coated bead, each of a series of beads was incubated for a different amount of time with 1 picomole of 5'-fluorescein-labelled oligonucleotide A which had been 3' end-labelled with ³²P. The percent of capture was determined for each bead and the results are shown below in Table III.

- 26 -

TABLE III

5	<u>Time</u>	Percent Oligonucleotide
		<u>Capture</u>
	0	0
	15 minutes	20
	30 minutes	45
10	1 hour	48
	2 hours	75
	3 hours	91
	4 hours	90
	5 hours	88
15	6 hours	86
	7 hours	85
	8 hours	82
	.	
	.	
20	.	
	20 hours	68

As illustrated in Table III, 90% of the 5' fluorescein-labelled oligonucleotide is captured by the bead in 2 to 3 hours. The slow decline in the amount of radiolabel over time on the bead most likely represents a small amount of leakage of the antibody from the bead.

(3) Experiment 1. The capture-efficiency of the anti-fluorescein-coated beads being established, 1 picomole of the first probe (5'-fluorescein-labelled oligonucleotide G), 1 picomole of the second probe (³²P-labelled oligonucleotide A), specific activity on date of use 3.2×10^6 cpm/picomole), and 1 picomole of the target (#2 SS, complementary to both the first and second probes) were diluted to 50 μ l with 5 X SSPE diluted from 20 X SSPE (3.6M NaCl; 0.23 M NaH₂PO₄, pH

- 27 -

7.5; and 20 mM EDTA). This hybridization solution was incubated for 3 hours at 50°C. This hybridization solution was diluted with 100 μ l of TDX buffer and one anti-fluorescein-coated bead was added. After
5 incubation for 3 hours at 25°C, the bead was washed with 1 ml of TDX buffer for 5 minutes at 37°C and was re-washed with 1ml of TDX buffer for 5 minutes at 37C before counting in a scintillation counter.

Control Experiments. Three control
10 experiments were run according to the same protocol but with the following modifications. In a first control experiment (Control 1), 5' fluorescein-labelled oligonucleotide G, as a first probe, and 5' ³²P-labelled oligonucleotide A, as a second probe, were incubated
15 with the anti-fluorescein-coated bead in the absence of any target. A second control experiment (Control 2) involved the use of 1 picomole of unlabelled oligonucleotide G as a first probe for the fluorescein-labelled oligonucleotide G of experiment 1. Finally, a
20 third control experiment (Control 3) was performed with 1 picomole of 5'-fluorescein-labelled oligonucleotide G, as a first probe, 1picomole of a ³²P-labelled oligonucleotide designated 32-B₂ (the sequence of which is not complementary to ϕ 2 SS), as a second probe, and 1
25 picomole of ϕ 2 SS as a target.

The results of these experiments are summarized in Table IV.

30

35

- 28 -

TABLE IV

<u>Experiment</u>	% ³² P Oligonucleotide <u>Bound to the Bead</u>
Experiment 1	4.2
Control 1	0.002
Control 2	0.07
Control 3	0.22

A comparison of Experiment 1 and Control 1 indicates that the hybrid comprising fluorescein-labelled oligonucleotide G, #2 SS, and ³²P-labelled oligonucleotide A may be selectively captured by an anti-fluorescein-coated solid support. Controls 2 and 3 demonstrate that in the absence of the correct antigen-labelled first probe or in the absence of the correct target complementary second probe, a hybrid is not effectively generated or captured.

Example 2

In an attempt to increase the capture efficiency of the hybridization assay according to the present invention, several fluorescein-labelled oligonucleotide probes were simultaneously introduced into the hybridization solution. Four experiments were run under identical reaction conditions.

A total of 250 femtomoles of fluorescein-labelled oligonucleotide was used in each experiment. In Experiment 1, 250 femtomoles of a single fluorescein-labelled oligonucleotide were used. The hybridization solution of Experiment 2 contained 125 femtomoles of each of two different fluorescein-labelled oligonucleotides, while Experiment 3 involved 83

- 29 -

femtomoles of each of three different fluorescein-labelled oligonucleotides in the hybridization solution. In Experiment 4, the hybridization solution contained 28 femtomoles of each of nine different
5 fluorescein-labelled oligonucleotides.

Specifically, in Experiment 1, a 5XSSPE solution of 250 femtomoles of 5' fluorescein-labelled oligonucleotide B, 25 femtomoles of a target #2 SS and 100 femtomoles of ³²P-labelled oligonucleotide A was
10 boiled for 5 minutes to denature any double-stranded secondary structure which might be present and incubated at 50°C for 3 hours. The hybridization solution was diluted with 50µl of 5XSSPE before adding one anti-fluorescein-coated bead. The bead was incubated in this
15 solution for 4 hours at 25°C and was washed in 1ml of 5 X SSPE for 5 minutes at 25°C before counting in a scintillation counter.

Experiment 2 duplicated the conditions of Experiment 1 except for the substitution of 125
20 femtomoles of each of 5' fluorescein-labelled oligonucleotides J and D in the place of the 250 femtomoles of 5' fluorescein-labelled oligonucleotide B.

In Experiment 3, the conditions of Experiment 1 were duplicated except for the substitution of 83
25 femtomoles of each of the 5' fluorescein-labelled oligonucleotides J, G, and D for the 250 femtomoles of 5' fluorescein-labelled oligonucleotide B of Experiment 1.

In Experiment 4, the conditions of Experiment 1 were duplicated except for the substitution of 28
30 femtomoles of each of the 5' fluorescein-labelled oligonucleotides B, C, D, E, F, G, H, I, and J for the 250 femtomoles of 5' fluorescein-labelled oligonucleotide B of Experiment 1.

35 The results of these four experiments are summarized in Table V, wherein the percentage of

- 30 -

sandwich hybridization complex captured by the bead is expressed as the ratio of ^{32}P oligonucleotide A captured per total amount of target present.

5

TABLE V

	<u>Percentage of Experiment</u>	<u>Complex Captured</u>
10	1	5.4
	2	14.2
	3	21.4
	4	61.2

15

As indicated in Table V, a roughly linear increase in hybridization efficiency was observed with increasing the number of different probes used. A 60% capture efficiency was achieved when all nine fluorescein oligonucleotides were used.

20

In general, the greater the number of points of stringency within a system, the less likely becomes the detection of false positives. In a conventional hybridization sandwich assay, the use of a separate probe for each of labelling and immobilization provides an additional point of stringency over use of a single probe for both purposes in that detection of a target sequence requires the occurrence of two independent events, i.e., the hybridization of both probes to the target. Consequently, it is believed that by the use of several first probes, the points of stringency are multiplied linearly, so that the efficiency of detection of a particular target sequence is increased relatively to the efficiency of detection of an incorrect sequence. Similarly, the use of a non-hybridization reaction to attach the first probe to the support serves to minimize detection of false positives by introducing a point of

35

- 31 -

stringency associated with an antibody/ antigen interaction into a system which already has a nucleic acid-related point of stringency and which would otherwise have only another nucleic acid- related point of stringency in its place.

In the following example, the linearity of the capture efficiency of a hybridization complex over a range of target concentrations (10 femtomoles to 16 attomoles) was investigated in two sets of experiments.

Example 3

In order to determine the effect of target concentration on the efficiency and sensitivity of the immuno-hybridization assay according to the present invention when run in the presence of extraneous DNA, the concentration of a target was varied from 10 femtomoles to 16 attomoles.

In each of six hybridization reactions, a solution of 111 femtomoles of each of 5' fluorescein-labelled oligonucleotides B, C, D, E, F, G, H, I, and J; 10µg of human placental DNA (available from Sigma Chemical Company, St. Louis, Missouri); and 100 femtomoles of ³²P-labelled oligonucleotide A in 5 X SSPE were prepared. To this basic solution, a varying amount of φ2 SS target was added. In Experiment 1, 10 femtomoles of target were added. In Experiment 2, 2 femtomoles of target was added. In Experiments 3, 4 and 5, 0.4 femtomoles, 0.08 femtomoles, and 0.016 femtomoles, respectively, of φ2SS target were added to the basic solution. In the Control experiment, no target was added.

The samples were boiled for 5 minutes and incubated for 1 hour at 50°C. Each sample was diluted with 400µl of 5 X SSPE containing 0.1% bovine gammaglobulin (Sigma Chemical Company, St. Louis,

- 32 -

Missouri), and 0.1% sodium azide (Aldrich Chemical, Milwaukee, Wisconsin). One anti-fluorescein-coated bead was added to each solution, and each solution was mixed at 220 rpm for 3 hours at 25°C. Each bead was then washed sequentially in 1ml of 5 X SSPE for 5 minutes at 25°C and in 1 ml of 5 X SSPE for 5 minutes at 37°C. Each of the beads was then counted on a scintillation counter. In Table VI, the percentage of sandwich hybridization complexes captured by the bead was calculated to be (^{32}P -labelled oligonucleotide A captured by the experimental bead - ^{32}P -labelled oligonucleotide A captured by the control bead) / (total amount of target present in the experiment) and averaged for two runs of each experiment.

TABLE VI

	<u>cpm Captured</u> <u>Experiment</u>	<u>% Complex</u> <u>by Bead</u>	<u>Captured</u>
20	1	13,182	53 (\pm 10)
	2	2,479	48 (\pm 9)
	3	630	52 (\pm 11)
	4	180	38 (\pm 13)
25	5	143	53 (\pm 9)
	Control	122	0

As indicated by the results in Table VI, the immuno-hybridization assay according to the present invention may detect the presence of target DNA in the attomole range as efficiently as in the femtomole range. Thus, the capture efficiency of the sandwich hybridization complex does not appear to be dependent upon the concentration of the target. The sensitivity of this system appears to be limited only by the

- 33 -

specific activity of the radioactively-labelled probe. Thus, an immuno-hybridization assay according to the present invention may be used to detect the presence of a very small quantity of DNA with very few manipulations
5 in a short period of time (4 to 5 hours).

In order to increase the sensitivity of the immuno-hybridization assay according to the present invention, a series of experiments was performed wherein a ^{32}P -labelled nick-translated DNA probe replaced the
10 ^{32}P -labelled oligonucleotide probe of the previous examples. As indicated in the following Example, the greater length of a nick-translated probe allows a larger amount of label to be attached, so that lower target concentrations may be detected.

15

Example 4

Five experimental mixtures were prepared. In each, a basic solution contained, as first probes, 111
20 femtomoles of each of 3' fluorescein-labelled oligonucleotides A-1, C-1, D-1, E-1, F-1, G-1, H-1, and J-1; 10 μg of human placental DNA (Sigma Chemical Company, St. Louis, Missouri); and 10 μg of a ^{32}P -labelled nick-translated plasmid second probe M13mpl8 Rf
25 (replicative form, i.e., double-stranded) having a specific activity at the time of use of 1.8×10^8 cpm/ μg in a 5 X SSPE solution diluted from 20 X SSPE. See, Maniatis, et al., Molecular Cloning, Cold Spring Harbor Laboratory, 109-112 (1982). To the basic solution, a
30 different amount of target NPE #1 single-stranded DNA was added in each experiment: in Experiment 1, 80 attomoles; in Experiment 2, 16 attomoles; in Experiment 3, 3 attomoles; in Experiment 4, 0.6 attomoles; and in the Control experiment, no target was added.

35

Each experimental solution was boiled for 5 minutes and then incubated for 17 hours at 50°C. Each

- 34 -

sample was diluted with 200 μ l of a capture buffer containing 5 X SSC (0.75 M NaCl; and 75 mM sodium citrate, pH 7.0); 0.1% non-fat dry milk according to the suggestion of Johnson, et al., Gene Anal. Techn., 1: 3-8 (1984); and 0.1% sodium azide. One anti-fluorescein coated bead was added to each of the solutions diluted with capture buffer, and each of the solutions was mixed at 200 rpm for 1 hour at 63°C. The beads were next washed successively in 1ml of 5 X SSC for 5 minutes at 25°C and in 1 ml of 5 X SSC for 5 minutes at 63°C. The beads were then counted in a scintillation counter. Two runs of each experiment were averaged to obtain the results as shown in Table VII.

15

TABLE VII

	<u>Experiment</u>	<u>cpm Capture by Bead</u>	<u>% Complex Captured</u>
20	1	2,579	5.6 (\pm 0.7)
	2	560	4.9 (\pm 0.5)
	3	220	5.0 (\pm 0.0)
	4	172	9.7 (\pm 0.0)
	Control	138	0

25

NPE #1 single-stranded phage DNA has 2.9 kilobases of HSVgD DNA cloned into M13mpl8. Thus, it was expected that the fluorescein-labelled first probes would complement portions of the gD sequence and that the second probe would complement portions of the M13mpl8 sequence. That these expectations were borne out is indicated in Table VII.

These experiments demonstrate that by increasing the sensitivity of the second probe, accomplished in this example by increasing the amount of label incorporated by the second probe, the limits of

35

- 35 -

the immuno-hybridization assay according to the present invention are expanded. As illustrated above, the use of a ^{32}P -labelled nick-translated DNA probe allows detection of sub-attomole quantities of target.

5 In the following example, the feasibility of detecting an immobilized hybridization complex by means of a non-radioactive detection system was explored. In this example, the second probe was 3'-labelled with a biotin group and 5'-labelled with ^{32}P . The resulting
10 immobilized hybridization complex may be detected by both a radioimmunoassay system and by an enzyme assay system, specifically the avidin:biotinylated Apase Complex discussed in Leary, et al., Proc.Natl. Acad.Sci. (USA), 80: 4045 (1983).

15

Example 5

Experiment: A 50 μl basal solution was prepared containing a total of 1picomole of fluorescein-labelled
20 first probes (111 femtomoles each of 3' fluorescein-labelled oligonucleotides A-1, C-1, D-1, E-1, F-1, G-1, H-1, I-1, and J-1); 100 femtomoles of 3' biotinylated, 5' ^{32}P -labelled oligonucleotide B-1 as a second probe; 10 femtomoles of NPE #1 as a target; and 10 μg of human
25 placental DNA (Sigma Chemicals, St. Louis, Missouri) in 5 X SSCE. The basic solution was boiled for 5 minutes and incubated at 63°C for 1 hour. The solution was diluted with 200 μl of capture buffer before adding an anti-fluorescein-coated bead. The bead-containing
30 mixture was incubated at 200 rpm for 1 hour at 63°C. The bead was then washed twice in 1 ml of 0.6 X SSC for 5 minutes at 63°C and counted in a scintillation counter.

The bead was next incubated in 500 μl of enzyme
35 solution (0.45 μg of biotinylated calf alkaline phosphatase (available from Boehringer Mannheim,

- 36 -

Indianapolis, Indiana), and biotinylated as described in Leary, et al., supra; 1.35 μ g of avidin DN, available from Vector Laboratories, Burlingame, California; 0.5 ml of NMZT buffer (3 M NaCl); 1 mM MgCl₂; 0.1 mM ZnCl₂; and 30 mM triethylaniline, pH 7.6); and 0.23% bovine serum albumin, available from Sigma Chemical Company, St. Louis, Missouri, for 1 hour at 25°C. The enzyme solution was prepared 30 minutes before use. After exposure to the enzyme solution, the bead was washed three times in 1 ml of SCSB buffer (50 mM sodium carbonate-bicarbonate, pH 9.0; 2 μ M ZnCl₂; 0.5mM MgCl₂; and 0.1 M NaCl) for 5 minutes at 25°C.

The bead was then placed in 500 μ l of enzyme substrate solution (10⁻⁴ M methylumbelliferone phosphate, available from Sigma Chemical Company, St. Louis, Missouri, in SCSB buffer) and incubated at 37°C. Ishikawa, et al., Scand.J. Immunol., 8: 43 (1978). After 1 hour of incubation, 400 μ l of this enzyme substrate solution was mixed with 100 μ l of enzyme killing solution (3.0 M K₂HPO₄, pH 10.4) and analyzed on a Perkin-Elmer 650S fluorescence detector (excitation 380 nm, emission 445 nm).

Control. A Control experiment mirrored the above Experiment except that no NPE #1 target was present.

The averaged results of two runs of each of Experiment 1 and the control experiment are shown in Table VIII. The "fluorescent units" are those generated by enzyme assay of the hybridization complex.

30

35

- 37 -

Table VIII

	<u>cpm Captured</u> <u>on Bead</u>	<u>% Complex</u> <u>Captured</u>	<u>Fluorescent</u> <u>Units</u>
5			
Experiment	1,281	20 (\pm 2)	217
Control	28	0	10

As indicated by the results shown in Table VIII, the immuno-hybridization assay according to the present invention may be used to quickly detect the presence of small quantities of target DNA by using a non-radioactive enzyme assay.

The feasibility of using an immuno-hybridization assay according to the present invention in order to detect the presence of double-stranded DNA using a non-radioactive detection system was explored in Example 6. Detection of double-stranded DNA is particularly desirable inasmuch as it is in this form that a sample of target DNA is likely to be presented in a clinical setting.

Example 6

Experiment. A target was obtained by Sac-1 (New England BioLabs, Beverly, Massachusetts) restriction endonuclease digestion of BamHI-J plasmid. A 2.9 kilobase fragment containing the gene coding for gD HSV-I was isolated by electrophoresis on agarose gel, followed by electroelution and ethanol precipitation. This fragment was denatured with base in boiling water, neutralized and stored on ice, prior to its use as a target.

A plasmid (pUCgD) containing nine copies of a probing sequence (bases 735-989 of Table I) was prepared by cloning the sequence into a pUC8 plasmid [Bethesda

- 38 -

Research Laboratories, Inc., Gaithersburg, Maryland] as an EcoRI-HindIII restriction fragment. The gD probing portion of this molecule was exposed by cutting the pUCgD plasmid with HindIII to form a linear probe and by
5 using exonuclease ExoIII [Bethesda Research Laboratories, Inc., Gaithersburg, Maryland] to digest the (+) strand of this plasmid revealing 3-4 copies of the probing sequence on the (-) strand. This partially single-stranded DNA was then treated with a biotinylated
10 psoralen derivative to generate a biotinylated second probe.

A 50 μ l solution was prepared, which solution contained: a total of 1.2 picomole of fluorescein-labelled oligonucleotide first probes; 100 femtomoles of
15 each of A-1, C-1, D-1, E-1, F-1, K-1, L-1, M-1, N-1, R-1, S-1, and T-1; 10 femtomoles of biotinylated-second probe; and 20 μ g of human placental DNA (Sigma Chemical Company, St. Louis, Missouri) in 5XSSCE. To this basic solution was added either 100, 30, 10 or 0 attomoles of
20 target with the "no target" experiment being the control.

The solution was boiled for 5 minutes and incubated at 50°C for 1 hour. The solution was diluted with 200 μ l of water and one anti-fluorescein-coated bead
25 was added. This mixture was incubated at 200 rpm for 1 hour at 50°C. The bead was washed with 1 ml of 5 X SSC for 5 minutes at 25°C, with 1 ml of 0.6 X SSC for 5 minutes at 50°C, and counted on a scintillation counter.

In all other respects, a first, second and
30 third Experiment and a Control experiment duplicated the materials and conditions set forth in Example 5.

The average of two runs of each of the Experiments and the Control are set forth in Table IX. In Table IX, the "fluorescent units" are those generated
35 by enzyme assay of the hybridization complex on the anti-fluorescein control bead.

- 39 -

TABLE IX

		Attomole <u>of Target</u>	Fluorescent <u>Units</u>
5			
	Experiment 1	100	487 \pm 5.5
	Experiment 2	30	236 \pm 18
10	Experiment 3	10	191 \pm 5.5
	Control	0	122 \pm 6.6

Thus, as is demonstrated by the results in Table IX, the immuno-hybridization system according to the present invention may be used to quickly detect the presence of small quantities of double-stranded target DNA using a non-radioactive enzyme assay.

It is expected that numerous modifications and variations will occur to those skilled in the art upon consideration of the present invention. For example, the component elements necessary to test a sample for the presence of a particular target DNA may be assembled in advance in the form of a kit. Specifically, a first probe complementary to a selected target and bound to a first immunological agent, a second probe bound to a reporter group and complementary to a different portion of the target than the first probe, and a second immunological agent bound to a support may be included in such a kit as separately packaged components. Such a kit may be used to detect the presence of and to quantify the target for which it was designed by combining the probes and support with a sample to be tested for target prepared, for example, according to the procedure of Ranki, et al., Curr. Top. Microbiol. Immunol., 104: 317-318 (1983).

Similarly, a kit may be prepared by associated

- 40 -

containers of a reporter-bound second probe, a second immunological agent-bound support and a mixture or separate container of several first probes, each being bound to a first immunological agent. Although the sequences of a plurality of first probes may overlap to some extent where required (i.e., different but overlapping), it is particularly desirable from the standpoint of assay sensitivity that the sequence of the second probe be separate (i.e., non-overlapping) from as well as different from that of any first probe in order to ensure that as much immobilized target as possible is labelled.

In addition, although the present invention has been described in terms of a system employing anti-fluorescein coated beads, materials are readily available for practicing the present invention with complexing agents. For example, agarose-bound lectins and biotinylated agarose are available from Vector Laboratories, Inc., Burlingame, California. Avidin-coated polymethacrylate spheres and biotin-labelled RNA may be obtained by the procedure of Manning, et al., Chromosoma (Berl.), 53: 107-117 (1979).

Therefore, it is intended that the present invention include all such equivalent variations which come within the scope of the invention as claimed.

30

35

- 41 -

WHAT IS CLAIMED IS:

1. A method for the isolation of a selected target nucleic acid sequence from a solution comprising the steps of:

(a) hybridizing a target sequence to a first single-stranded nucleic acid probe having a sequence complementary to a first portion of the target nucleic acid sequence, the first probe being attached to a first complexing agent;

(b) immobilizing the first probe by exposing the first probe to a support-bound second complexing agent capable of stably binding to the first complexing agent to form a complex; and

~~(c) introducing a second single-stranded~~ nucleic acid probe having a sequence complementary to a second portion of the target sequence, the second probe being attached to a reporter group;

wherein said first and second complexing agents are selected from the group consisting of an antigen and an antibody to the antigen, and a lectin and a carbohydrate.

2. The method as recited in claim 1 further comprising the step of:

separating the solution from the immobilized hybrid sequence.

3. The method as recited in claim 1 wherein the target sequence is a double-stranded sequence and wherein the method as recited in claim 1 further comprises the step of making a single-stranded portion of a double-stranded sequence available for hybridization.

- 42 -

4. The method as recited in claim 1 wherein the target sequence is a single-stranded sequence.

5. The method as recited in claim 1 wherein the first complexing agent is an antibody and wherein the second complexing agent is an antigen.

6. The method as recited in claim 1 wherein the first complexing agent is an antigen and wherein the second complexing agent is an antibody.

7. The method as recited in claim 6 wherein the antigen is fluorescein and wherein the antibody is an anti-fluorescein antibody.

8. The method as recited in claim 1 wherein the first complexing agent is a carbohydrate and wherein the second complexing agent is a lectin.

9. The method as recited in claim 1 wherein the first complexing agent is a lectin and wherein the second complexing agent is a carbohydrate.

10. The method as recited in claim 1 further comprising the step of:

(d) assaying for the reporter group.

11. The method as recited in claim 10 wherein the target sequence is a double-stranded sequence and wherein the method as recited in claim 10 further comprises the step of making a single-stranded portion of a double-stranded sequence available for hybridization.

12. The method as recited in claim 10 wherein the target sequence is a single-stranded sequence.

- 43 -

13. The method as recited in claim 10 wherein the first complexing agent is an antibody and wherein the second complexing agent is an antigen.

5

14. The method as recited in claim 10 wherein the first complexing agent is an antigen and wherein the second complexing agent is an antibody.

10

15. The method as recited in claim 14 wherein the antigen is fluorescein and wherein the antibody is an anti-fluorescein antibody.

15

16. The method as recited in claim 10 wherein the first complexing agent is a carbohydrate and wherein the second complexing agent is a lectin.

20

17. The method as recited in claim 10 wherein the first complexing agent is a lectin and wherein the second complexing agent is a carbohydrate.

25

18. The method as recited in claim 1 wherein the reporter group comprises an isotopic label covalently attached to the second probe sequence.

30

19. The method as recited in claim 1 wherein the reporter group comprises a radioactive heavy metal attached to the second probe by a chelating moiety.

20. The method as recited in claim 1 wherein the reporter group is non-radioactive.

35

21. The method as recited in claim 20 wherein the non-radioactive reporter group comprises biotin and wherein the method according to claim 1 further comprises the steps of:

- 44 -

complexing the biotin in the reporter group
with an avidin moiety;

forming a complex of the avidin with a
biotinylated calf alkaline phosphatase moiety; and

5 reacting the avidin-complexed biotinylated
calf alkaline phosphatase moiety with
methylumberliferone phosphate.

22. The method as recited in claim 1 wherein
10 said hybridizing step precedes said immobilizing step.

23. The method as recited in claim 1 wherein
said immobilizing step precedes said hybridizing step.

15 24. The method as recited in claim 1 wherein
said hybridizing step precedes said immobilizing step.

25. The method as recited in claim 1 wherein
said immobilizing step precedes said hybridizing step.

20

26. A kit for performing a hybridization
assay on a sample containing a selected target nucleic
acid sequence comprising:

25 a first probe having a nucleic acid sequence
complementary to a first portion of the target nucleic
acid sequence;

a first complexing agent attached to said
first probe;

30 a second single-stranded nucleic acid probe
associated with said first probe, having a nucleic acid
sequence complementary to a second portion of said
target sequence;

a reporter group attached to said second
probe;

35 a solid support associated with said first
probe; and

- 45 -

a second complexing agent attached to said solid support, having a binding portion complementary to said first complexing agent binding portion;

5 wherein said first and second complexing agents are selected from the group consisting of an antigen, an antibody to the antigen, a lectin, and a carbohydrate.

10 27. The kit as recited in claim 26 wherein said first complexing agent is an antibody and wherein said second complexing agent is an antigen.

15 28. The kit as recited in claim 26 wherein said first complexing agent is an antigen and wherein said second complexing agent is an antibody.

20 29. The kit as recited in claim 27 wherein said antibody is an anti-fluorescein antibody and wherein said antigen is fluorescein.

30. The kit as recited in claim 26 wherein said first complexing agent is a carbohydrate and wherein said second complexing agent is a lectin.

25 31. The kit as recited in claim 26 wherein said first complexing agent is a lectin and wherein said second complexing agent is a carbohydrate.

30 32. The kit as recited in claim 26 wherein said detectable label is an isotopic label covalently attached to said second probe sequence.

35 33. The kit as recited in claim 26 wherein said detectable label is a radiolabelled heavy metal attached to said second probe by a chelating moiety.

- 46 -

34. The kit as recited in claim 26 wherein said detectable label is a non-radioactive label.

5 35. The kit as recited in claim 34 wherein said non-radioactive label comprises biotin and wherein the kit further comprises:

avidin, biotinylated calf alkaline phosphatase, and methylumbelliferone phosphate, all associated with said first probe.

10

36. A method for increasing the capture efficiency associated with immobilizing a target nucleic acid sequence on a solid support comprising the steps of:

15

exposing the target nucleic acid sequence to at least two first probes, each having a nucleic acid sequence complementary to a different portion of the target nucleic acid sequence and each having a support-binding portion;

20

hybridizing in solution the target nucleic acid sequence with at least one of the first probes; and attaching the support-binding portion of the at least one of the first probes to a first probe-binding portion on a solid support.

25

37. The method as recited in claim 36 further comprising the step of introducing a second, single-stranded, nucleic acid probe having a sequence complementary to a portion of the target nucleic acid sequence which is separate from any portion complementary to any first probe, and being attached to a reporter group.

35

- 47 -

38. A kit for performing a hybridization assay on a sample containing a selected target nucleic acid sequence comprising:

- 5 at least two first probes, each having a nucleic acid sequence complementary to a different portion of the target nucleic acid sequence and each having a support-binding portion;
- 10 a second probe, associated with said first probes, having a sequence complementary to a portion of the target nucleic acid sequence separate from any portion complementary to any first probe and being attached to a reporter group; and
- 15 a solid support, associated with said first probes, having a first probe-binding portion.

15

20


25

30

35

INTERNATIONAL SEARCH REPORT

International Application No PCT/US86/01280

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC		
INT. CL ⁴ : C12Q 1/68; G01N 33/53; C12N 15/00		
U.S. CL : 435/6,7; 935/78		
II. FIELDS SEARCHED		
Minimum Documentation Searched *		
Classification System	Classification Symbols	
U.S.	435/6,7,21,803,810 436/501,528,800,808,824,827 935/12,15,78	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *		
Computer Search: Chemical Abstracts 1976-1986; Biosis 1977-1986		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴		
Category *	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
Y	US,A, 4,358,535 (FALKOW ET AL) 09 November 1982 see Column 3, lines 25-47; Column 4, lines 5-20.	2-7,10- 15,18-29, 32-35
Y	US,A, 4,486,539 (RANKI ET AL) 04 December 1984 see Column 2, lines 1-20	1-37
Y	US,A, 4,556,643 (PAUU ET AL) 03 December 1985 see column 5, lines 54-60; Column 8, lines 64-67; Column 11, lines 44-51 and 59-62.	5-7,13-15, 26-29
P,Y	US,A, 4,563,417 (ALBARELLA ET AL) 07 January 1986 see Column 3, lines 13-19.	5-7,13-15, 26-29
<p>* Special categories of cited documents: ¹⁵</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search ¹	Date of Mailing of this International Search Report ²	
25 August 1986	04 SEP 1986	
International Searching Authority ³	Signature of Authorized Officer ²⁰	
ISA/US	 JEREMY M. JAY	

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

P,Y	US,A, 4,581,333 (KOURILSKY ET AL) 08 April 1986 see Column 3, lines 40-55.	20,21,34, 35
P,Y	US,A, 4,582,789 (SHELDON, III ET AL) 15 April 1986 see Column 3, lines 40-55	3,11

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹⁰

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers because they relate to subject matter ¹² not required to be searched by this Authority, namely:
2. ☐ Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out ¹³, specifically:

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ¹¹

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No ¹⁸
P, Y	EP, A, 0,151,492 (Enzo Biochem) 14 August 1985 see pages 3, lines 27-30; 6, lines 4-6; 7, lines 16-24.	1-37 .
Y	EP, A, 0,139,489 (Ortho Diagnostic Systems) 05 February 1986 see page 2, lines 17-23.	2-17, 20- 31, 34, 35
Y	US, A, 4,455,380 (ADACHI) 19 June 1984 see Column 5, lines 16-20, 34-54	8, 9, 16, 17, 26, 30, 31
Y	US, A, 4,478,914 (GIESE) 23 October 1984 see column 5, lines 23-40	8, 9, 16, 17, 20, 21, 26, 30, 31
Y	US, A, 4,256,834 (ZUK ET AL) 17 March 1981 see column 21, lines 47-50; column 27, line 1	7, 15, 29, 35